What is it?
Human chorionic gonadotropin, or hCG, is a placental hormone that acts much like the reproductive signal called luteinizing hormone.
Gathering the record
Loading the next view…
Relay is organizing the evidence and source boundaries.
Gathering the record
Relay is organizing the evidence and source boundaries.
Placental glycoprotein hormone and LH-receptor agonist
HCG is a placental hormone that acts much like luteinizing hormone. Approved products are used in carefully defined fertility and endocrine settings, including triggering final egg maturation or ovulation and selected male hypogonadotropic hypogonadism. People also discuss it alongside testosterone therapy, but the clearest study there is a short intratesticular-testosterone biomarker trial—not proof of maintained fertility. HCG is not a supported weight-loss or appetite-suppression treatment.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Human chorionic gonadotropin, or hCG, is a placental hormone that acts much like the reproductive signal called luteinizing hormone.
Its predictable reproductive effects support specialist use in fertility treatment and selected forms of hormone deficiency. Researchers have also examined narrower male hormone questions and repeatedly tested unsupported weight-loss claims.
Specific approved products can trigger final egg maturation or ovulation in monitored fertility programs and support selected male endocrine uses. Short male studies show hormone biomarkers, not guaranteed fertility preservation. Controlled evidence does not support hCG as a weight-loss treatment.
Long-term off-label use alongside testosterone, comparative fertility strategies, and the identity and handling of nonapproved products remain uncertain. Urinary and recombinant products differ, and no single preparation rule applies across them.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Regulatory evidence describes a specific recombinant hCG product in monitored assisted-reproduction and ovulation-induction programs.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Approved fertility products, monitored reproductive programs, male hypogonadotropic-hypogonadism studies, pharmacology experiments, and negative obesity trials are available.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Effectiveness is well established for specific fertility and gonadotropin-deficiency settings, but product, route, population, and co-treatment determine what the evidence means.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The evidence applies to a defined fertility program and a specific prefilled product. It does not support unmonitored use, weight loss, or transfer of handling instructions to urinary, compounded, or research products. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Multiple approved reproductive-endocrine indications supported by product-specific controlled programs and decades of condition-specific human research.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Long-term benefit and safety of off-label hCG alongside testosterone, comparative fertility strategies, and the identity and handling of nonapproved products.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
It stimulates Leydig-cell androgen production in the testes and supports progesterone production by the corpus luteum; in a monitored ovarian cycle it can substitute for the mid-cycle LH surge.
Current labels cover monitored female fertility uses and, for certain urinary products, selected male hypogonadotropic hypogonadism and prepubertal cryptorchidism not caused by an anatomic obstruction.
Condition-specific studies show increased testosterone and sperm production, but response depends on pubertal onset, testicular size, cryptorchidism history, treatment duration, and whether FSH activity is added.
A three-week randomized study showed dose-related preservation of intratesticular testosterone when hCG was added to testosterone.
In a three-month randomized comparison, hCG, clomiphene, and their combination all raised testosterone and symptom scores.
A placebo-controlled trial found no advantage, FDA says no hCG product is approved for weight loss, and current labeling states that hCG has no known effect on fat mobilization, hunger, or fat distribution.
Labels warn about ovarian hyperstimulation syndrome, ovarian enlargement or torsion, multiple gestation, and pulmonary or vascular complications.
Androgen stimulation can increase water and sodium retention; current urinary-hCG labeling also lists sporadic gynecomastia and systemic or local reactions.
Pregnyl and Novarel are urinary-derived powders labeled for intramuscular use after reconstitution, while Ovidrel is a recombinant single-use subcutaneous prefilled solution.
Current labeled products differ: Pregnyl permits up to 60 days refrigerated after its specified reconstitution, Novarel says 30 days, and Ovidrel is supplied as a single-use prefilled solution that is not reconstituted.
Current labels warn about assay cross-reactivity and false-positive pregnancy tests after administration.
Mechanisms
Human chorionic gonadotropin is a heterodimeric glycoprotein whose alpha subunit is shared with LH, FSH, and TSH while its beta subunit provides specificity. Binding to the luteinizing hormone/choriogonadotropin receptor stimulates Leydig-cell androgen production and ovarian luteinization. Urinary-derived chorionic gonadotropin and recombinant choriogonadotropin alfa have product-specific approvals, routes, presentations, units, and handling instructions. Controlled and observational human research supports monitored fertility and defined hypogonadotropic-hypogonadism uses. Short off-label studies show effects on intratesticular or serum testosterone, but do not by themselves demonstrate long-term fertility preservation. Controlled obesity research and FDA labeling contradict hCG diet claims.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Open-label, three-arm randomized controlled trial
45 adult men with congenital hypogonadotropic hypogonadism
Spermatogenesis occurred in 84.6%, 69.2%, and 75% across the three strategies, with no significant difference. The triple-therapy strategy used less hCG at spermatogenesis and reported better quality-of-life measures.
Study administration: hCG plus FSH plus testosterone, hCG plus FSH, or hCG followed by hCG plus FSH
Limitations: The study was small, open-label, and limited to congenital hypogonadotropic hypogonadism. All arms were active strategies, and it does not establish a general hCG protocol.
Three-arm randomized trial
282 men with hypogonadism who wished to preserve fertility
Testosterone and symptom scores increased in all three groups over three months. Testosterone restoration did not differ significantly between the groups.
Study administration: Clomiphene, hCG, or their combination
Limitations: The trial was short and did not report semen, pregnancy, live-birth, or long-term safety outcomes. A desire to preserve fertility is not the same as demonstrated fertility preservation.
Randomized dose-response biomarker study
29 healthy men with experimentally suppressed gonadotropins
Testosterone plus placebo suppressed intratesticular testosterone by 94%. Adding hCG produced a dose-related preservation of intratesticular testosterone.
Study administration: Testosterone enanthate plus saline or one of three protocol-defined hCG arms
Limitations: This was a three-week biomarker experiment. It did not establish maintenance of sperm count, pregnancy, long-term fertility, symptom benefit, or long-term safety, and its protocol is not personal dosing guidance.
Double-blind, placebo-controlled trial
40 women with obesity receiving the same calorie-restricted diet
hCG provided no advantage over placebo for any measured outcome. The authors found no rationale for hCG injections as an obesity treatment.
Study administration: Intramuscular hCG or saline placebo six days per week
Limitations: This was a small older trial, but its null finding aligns with current product labeling and FDA's explicit rejection of hCG weight-loss claims.
Single-center retrospective treatment cohort
223 azoospermic men with congenital hypogonadotropic hypogonadism and absent pubertal development
Testicular volume and testosterone increased, and 64% produced sperm. Larger starting testicular volume and no history of cryptorchidism predicted earlier sperm appearance; 19 of 34 men seeking fatherhood achieved partner pregnancy.
Study administration: Combined hCG and human menopausal gonadotropin
Limitations: This was retrospective combination therapy in a defined congenital disorder. It cannot isolate hCG's contribution or generalize to nonspecific low testosterone or fertility preservation during testosterone use.
Sequential gonadotropin treatment study
21 men with hypogonadotropic hypogonadism
Normal sperm counts developed with hCG alone in all six men whose hypogonadism began after puberty, but in only one of 15 with prepubertal onset. Adding hMG helped some remaining men, especially those without cryptorchidism.
Study administration: hCG alone, followed by added human menopausal gonadotropin when needed
Limitations: This was small and condition-specific. Response depended strongly on disease history, and hCG alone was often insufficient in prepubertal-onset disease.
Two assisted-reproduction studies and one ovulation-induction study summarized in the approved label
Women undergoing assisted reproductive technology or ovulation induction after monitored follicular development
The approved Ovidrel program established product-specific effectiveness for final follicular maturation and ovulation induction. In the label's ovulation-induction study, 91.9% ovulated and 22% had a clinical pregnancy; multiple births occurred among reported live births.
Study administration: Product-specific subcutaneous recombinant choriogonadotropin alfa compared with urinary hCG or used after follicular stimulation
Limitations: These results apply to a monitored infertility program and a specific recombinant prefilled product. They are not evidence for unmonitored use or for urinary, compounded, or research products.
Safety snapshot
Male adverse effects can include fluid retention, gynecomastia, mood symptoms, headache, and injection-site reactions.
Other human evidenceA label lists recognized events but does not provide a personalized probability or establish safety for unapproved products and uses.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryFDA approved in product-specific formulations for defined fertility and endocrine indications Long-term benefit and safety of off-label hCG alongside testosterone, comparative fertility strategies, and the identity and handling of nonapproved products.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-04-01 · PMID 41993983 · CTRI/2022/05/042795 · DOI 10.3389/fendo.2026.1777584
2025-03-01
2023-07-01
2023-05-01
2022-03-30
2018-11-01 · PMID 29772111 · DOI 10.1111/bju.14401
2016-03-01 · PMID 26945370 · DOI 10.1097/MD.0000000000002867
2005-05-01 · PMID 15713727 · DOI 10.1210/jc.2004-0802
1990-02-17 · PMID 2405506
1985-09-12 · PMID 3927163 · DOI 10.1056/NEJM198509123131102